$IOVA

Johnson & Johnson and Pfizer are targeting early-stage cancer assets, focusing on Sellas Life Sciences (SLS), ImmunityBio (IBRX), and Iovance Biotherapeutics (IOVA). SLS's SLS009 showed 46%-50% response rates in AML, while Iovance expects lung-cancer data in Q4. J&J's CEO highlighted M&A interest in early-stage opportunities, with recent deals like Halda Therapeutics and Firefly Bio. IOVA, IBRX, and SLS stocks rose 8%, 6%, and 2% respectively on Monday.

Iovance Biotherapeutics (IOVA) hit a 52-week high of $9.36, with a market cap of $4.2B. The stock is up 215% YTD and 279% over one year. Q2 2026 revenue was $99.31M, beating estimates. UBS raised its price target to $7.00 (Neutral), while TD Cowen raised it to $10.00 (Buy).

Iovance Biotherapeutics (IOVA) shares rose 30% after reporting record Q4 margins and revenue of $86.7M, beating estimates. Analyst Chardan lowered its price target to $16, implying 323% upside, citing operational improvements and pipeline advancements. The company expects revenue growth in 2026 and potential for Amtagvi and Proleukin to reach $1B in peak U.S. sales.

Iovance Biotherapeutics (IOVA) reported strong commercial momentum at the Wells Fargo Healthcare Conference. AMTAGVI sales reached $91M in Q2 2024, up 51.7% from Q1, with improved margins to 56%. PROLEUKIN sales declined but are expected to rebound. The company expects continued growth and updated guidance later this quarter. IOV-LUN-202 lung cancer study is on track for data in Q4 2024.

Iovance (IOVA) shares dropped 15% after Q1 earnings missed estimates, with revenue at $71.4M vs. $75.6M expected. The company faces delays in U.K. and EU approvals for its cancer therapy, Amtagvi. Q2 revenue is forecasted between $86M-$88M, and FY26 between $350M-$370M.

Iovance Biotherapeutics (IOVA) received FDA clearance for a Phase I/II trial for its IOV-5001 therapy. The stock has surged 75.74% in 30 days and 227.78% year-to-date, but is down 66.29% over 5 years. Analysts suggest it may be 54% undervalued at $8.26, with a fair value estimate of $18.00, citing potential market expansion and revenue growth.

Amylyx Pharmaceuticals (AMLX) surged 63% after reporting positive Phase 3 trial results for avexitide, with Stifel doubling its price target to $45. Iovance Biotherapeutics (IOVA) hit a 52-week high, driven by Q2 earnings and a price target increase from Mizuho. ONEOK (OKE) reached a 52-week high following strong Q2 earnings, raised 2026 guidance, and a new supply deal, with Morgan Stanley raising its target to $105.

Iovance Biotherapeutics (IOVA) reported early clinical trial results showing lifileucel, its tumor-infiltrating lymphocyte therapy, achieved tumor responses in half of six evaluable patients with advanced soft tissue sarcomas. The company plans a registrational trial and FDA consultation for expedited review. IOVA stock rose over 5% in premarket trading. Q4 revenue was $87M, up 30% YoY, with a 50% gross margin. IOVA stock has fallen 47% over the past year.

Iovance Biotherapeutics (IOVA) granted 20 new employees options for 240,135 shares at $8.99 each, the closing price on August 20, 2026. The options vest over three years, with one-third vesting after one year and the rest in quarterly installments. The company operates under NASDAQ Listing Rule 5635(c)(4).

Iovance Biotherapeutics (IOVA) surged 12% to a 52-week high after reporting Q2 revenue of $99.3M and a UBS price target raise. Amylyx Pharmaceuticals (AMLX) rose 2% on positive Phase 3 trial results and a $500M offering. ConocoPhillips (COP) gained 3% after strong Q2 earnings and a Morgan Stanley price target increase.